Csenge Advisory Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.33M | Sell |
25,158
-10,330
| -29% | -$2.22M | 0.26% | 76 |
|
|
2026
Q1 | $7.72M | Sell |
35,488
-620
| -2% | -$138K | 0.35% | 51 |
|
|
2025
Q4 | $8.25M | Buy |
36,108
+12,983
| +56% | +$2.96M | 0.37% | 50 |
|
|
2025
Q3 | $5.35M | Sell |
23,125
-1,671
| -7% | -$340K | 0.26% | 78 |
|
|
2025
Q2 | $4.61M | Sell |
24,796
-244
| -1% | -$45.3K | 0.24% | 83 |
|
|
2025
Q1 | $4.33M | Buy |
25,040
+2,926
| +13% | +$569K | 0.25% | 82 |
|
|
2024
Q4 | $3.93M | Sell |
22,114
-444
| -2% | -$81.6K | 0.21% | 93 |
|
|
2024
Q3 | $4.38M | Sell |
22,558
-278
| -1% | -$51.9K | 0.23% | 88 |
|
|
2024
Q2 | $3.92M | Buy |
22,836
+1,222
| +6% | +$202K | 0.22% | 89 |
|
|
2024
Q1 | $3.94M | Sell |
21,614
-847
| -4% | -$146K | 0.22% | 84 |
|
|
2023
Q4 | $3.48M | Sell |
22,461
-948
| -4% | -$138K | 0.22% | 81 |
|
|
2023
Q3 | $3.49M | Buy |
23,409
+963
| +4% | +$141K | 0.24% | 80 |
|
|
2023
Q2 | $3.02M | Buy |
22,446
+1,648
| +8% | +$242K | 0.2% | 95 |
|
|
2023
Q1 | $3.31M | Buy |
20,798
+770
| +4% | +$118K | 0.24% | 82 |
|
|
2022
Q4 | $3.24M | Buy |
20,028
+1,412
| +8% | +$217K | 0.25% | 78 |
|
|
2022
Q3 | $2.5M | Sell |
18,616
-833
| -4% | -$120K | 0.21% | 92 |
|
|
2022
Q2 | $2.98M | Sell |
19,449
-2,793
| -13% | -$427K | 0.25% | 79 |
|
|
2022
Q1 | $3.61M | Buy |
22,242
+2,078
| +10% | +$302K | 0.29% | 67 |
|
|
2021
Q4 | $2.3M | Sell |
20,164
-3,355
| -14% | -$396K | 0.21% | 92 |
|
|
2021
Q3 | $2.57M | Buy |
23,519
+3,355
| +17% | +$383K | 0.22% | 88 |
|
|
2021
Q2 | $2.3M | Buy |
20,164
+3,377
| +20% | +$380K | 0.2% | 92 |
|
|
2021
Q1 | $1.8M | Buy |
16,787
+4,358
| +35% | +$466K | 0.18% | 93 |
|
|
2020
Q4 | $1.33M | Buy |
12,429
+471
| +4% | +$45.3K | 0.16% | 105 |
|
|
2020
Q3 | $1.03M | Sell |
11,958
-2,850
| -19% | -$268K | 0.14% | 121 |
|
|
2020
Q2 | $1.45M | Buy |
14,808
+9,919
| +203% | +$873K | 0.21% | 91 |
|
|
2020
Q1 | $372K | Buy |
+4,889
| New | +$416K | 0.1% | 181 |
|
|
2019
Q1 | – | Sell |
-8,774
| Closed | -$808K | – | 193 |
|
|
2018
Q4 | $808K | Buy |
8,774
+894
| +11% | +$78.6K | 0.3% | 74 |
|
|
2018
Q3 | $695K | Sell |
7,880
-5,533
| -41% | -$525K | 0.27% | 69 |
|
|
2018
Q2 | $1.24M | Sell |
13,413
-9,291
| -41% | -$907K | 0.46% | 52 |
|
|
2018
Q1 | $2.15M | Sell |
22,704
-7,425
| -25% | -$816K | 0.75% | 23 |
|
|
2017
Q4 | $2.91M | Sell |
30,129
-425
| -1% | -$40.1K | 1.04% | 16 |
|
|
2017
Q3 | $2.72M | Buy |
+30,554
| New | +$2.33M | 1.07% | 15 |
|
Other funds holding ABBV
Csenge Advisory Group's ABBV Position: Q2 2026 in Review
Csenge Advisory Group reduced its AbbVie (ABBV) stake by 29% in Q2 2026, selling an estimated $2.22M and leaving 25,158 shares worth $6.33M. The position accounts for 0.26% of the portfolio, ranked #76.
Csenge Advisory Group first reported a position in ABBV in Q3 2017 and has held it in 32 quarters since. The position peaked at $8.25M in Q4 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Csenge Advisory Group held 25,158 shares of AbbVie worth $6.33M as of Q2 2026.
- Csenge Advisory Group sold 10,330 AbbVie shares in Q2 2026, an estimated $2.22M.
- AbbVie made up 0.26% of Csenge Advisory Group's portfolio in Q2 2026, its #76 holding.
- Csenge Advisory Group first reported a position in AbbVie in Q3 2017 and has held it in 32 quarters since.
- Csenge Advisory Group's AbbVie position peaked at $8.25M in Q4 2025.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.